At the Centre of Pharmaceutical Policy & Regulation, we aim to develop, assess, and apply innovative methods in pharmaceutical policy, drug regulatory science, and health technology assessment (HTA). We take an integrated approach to the drug life cycle, considering the context in which medicines are developed, assessed, and used. Our focus is on addressing critical research questions related to the authorisation, access, and affordability of medicines.
One of the unique aspects of our Centre is that we work closely with experts from the Dutch Medicines Evaluation Board (MEB), the Dutch National Health Care Institute (ZIN), and the International Pharmaceutical Federation (FIP). Embedded within our Centre is the WHO Collaborating Centre for Pharmaceutical Policy and Regulation, where we focus on global aspects of access to medicines in pharmaceutical systems. We are also proud to be partners in the Regulatory Science Network Netherlands (RSNN) and the Academic Research Network HTA.
